IC
ANAB icon

Ikarian Capital’s AnaptysBio ANAB Stock Holding History

Ikarian Capital’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48,410
Closed -$1.48M – 179
2025
Q3 		$1.48M Buy
48,410
+32,748
+209% +$752K 0.15% 108
2025
Q2 		$348K Buy
+15,662
New +$328K 0.07% 100
2021
Q3 		– Sell
-21,553
Closed -$558K – 219
2021
Q2 		$558K Buy
21,553
+12,000
+126% +$288K 0.05% 183
2021
Q1 		$207K Sell
9,553
-90,447
-90% -$2.28M 0.01% 272
2020
Q4 		$2.15M Buy
100,000
+50,000
+100% +$1.21M 0.09% 153
2020
Q3 		$738K Buy
50,000
+45,419
+991% +$819K 0.05% 134
2020
Q2 		$102K Buy
+4,581
New +$83.7K 0.01% 153
2020
Q1 		– Sell
-143,000
Closed -$2.32M – 153
2019
Q4 		$2.32M Buy
+143,000
New +$3.38M 0.38% 59

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Ikarian Capital's ANAB Position: Q4 2025 in Review

Ikarian Capital sold out of AnaptysBio (ANAB) in Q4 2025, closing a stake of 48,410 shares — an estimated $1.48M sold.

Ikarian Capital first reported a position in ANAB in Q4 2019 and held it in 8 quarters. The position peaked at $2.32M in Q4 2019. 179 funds tracked by Wall St. Rank hold ANAB as of Q4 2025.

  • Ikarian Capital reported no remaining AnaptysBio position as of Q4 2025 after selling out during the quarter.
  • Ikarian Capital sold 48,410 AnaptysBio shares in Q4 2025, an estimated $1.48M.
  • Ikarian Capital first reported a position in AnaptysBio in Q4 2019 and held it in 8 quarters.
  • Ikarian Capital's AnaptysBio position peaked at $2.32M in Q4 2019.
  • 179 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.